Skip to main content
. 2023 Apr 6;14:1129465. doi: 10.3389/fimmu.2023.1129465

Figure 5.

Figure 5

The current clinical strategies and future perspectives in NSCLC patients after immunotherapy resistance. The selection of clinical treatment for NSCLC progression after immunotherapy resistance should be dependent on the progressive mode. Further studies can pay attention to optimizing the combined therapy and exploring strategies to modulate infiltrating immune cells and timely reshape TME.